Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration

G. Mountzios; J. Remon; S. Novello; N. Blais; R. Califano; T. Cufer; A. M. Dingemans; S. V. Liu; N. Peled; N. A. Pennell; M. Reck; C. Rolfo; D. Tan; J. Vansteenkiste; H. West; B. Besse

doi:10.1093/annonc/mdz295

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration

G. Mountzios^*
, J. Remon
, S. Novello
, N. Blais
, R. Califano
, T. Cufer
, A. M. Dingemans
, S. V. Liu
, N. Peled
, N. A. Pennell
, M. Reck
, C. Rolfo
, D. Tan
, J. Vansteenkiste
, H. West
, B. Besse

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	1686-1688
Number of pages	3
Journal	Annals of Oncology
Volume	30
Issue number	11
DOIs	https://doi.org/10.1093/annonc/mdz295
Publication status	Published - Nov 2019

Keywords

NIVOLUMAB
DOCETAXEL
1ST-LINE

Access to Document

10.1093/annonc/mdz295Licence: CC BY-NC-ND

Cite this

Mountzios, G., Remon, J., Novello, S., Blais, N., Califano, R., Cufer, T., Dingemans, A. M., Liu, S. V., Peled, N., Pennell, N. A., Reck, M., Rolfo, C., Tan, D., Vansteenkiste, J., West, H., & Besse, B. (2019). Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration. Annals of Oncology, 30(11), 1686-1688. https://doi.org/10.1093/annonc/mdz295

@article{b11276925de3431385a4292159d43006,

title = "Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1\% by the USA Food and Drug Administration",

keywords = "NIVOLUMAB, DOCETAXEL, 1ST-LINE",

author = "G. Mountzios and J. Remon and S. Novello and N. Blais and R. Califano and T. Cufer and Dingemans, \{A. M.\} and Liu, \{S. V.\} and N. Peled and Pennell, \{N. A.\} and M. Reck and C. Rolfo and D. Tan and J. Vansteenkiste and H. West and B. Besse",

note = "Funding Information: GM received honoraria/consultancy from AstraZeneca, Roche, Pfizer, BMS, MSD, Takeda, Boehringer, Merck, Novartis, Amgen; received travel fees from AstraZeneca, Roche, Pfizer, BMS, MSD, Takeda, Boehringer, Merck, Novartis, Astellas, Pierre Fabre. JR: Other from MSD (advisory), other from BOEHRINGER (advisory), other from PFIZER (advisory), personal fees and other from OSE IMMUNOTHERAPEUTICS (travel), other from BMS (travel and advisory), other from ASTRAZENECA (travel and advisory), other from ROCHE (travel), outside the submitted work. SN is a advisor/speaker bureau for Astra Zeneca, BI, Celgene, Eli Lilly, MSD, Takeda, Pfizer, Roche, BMS, Abbvie. NB is a consultant honorarium to Pfizer, AZ, BMS, Merck, BI, Novartis, Takeda, Sanofi, Roche; received research grants from CCTG, Astra Zeneca. RC received honoraria and consultancy fees from AstraZeneca, Boehringer Ingelheim, Lilly Oncology, Roche, Pfizer, MSD, BMS, Takeda, and Novartis. TC received honoraria for lectures and advisory board consultations from AstraZeneca. AMD is an advisory board member of BMS, MSD, Roche, Eli Lilly, Takeda, Pfizer, Boehringer Ingelheim (all institution); received research grant from BMS (institution); received research support from Abbvie (institution). SL is an advisory board/consultant of Apollomics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Guardant Health, Heron, Ignyta, Inivata, Janssen, Lilly, Merck, Pfizer, Regeneron, Taiho (DSMB), Takeda/Ariad, Tempus; received research grant (institution) from Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Clovis, Corvus, Debiopharm, Esanex, Genentech/Roche, Ignyta, Lilly, Lycera, Merck, Molecular Partners, OncoMed, Pfizer, Rain Therapeutics. NP is an advisor for and honorarium from AstraZeneca, AID Genomics, Boehringer-Ingelheim, BMS, E.Lilly, MSD, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360. NP received consulting fees from AstraZeneca, Merck, Eli Lilly, BMS, and Cota. MR: Amgen, Abbvie, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, Roche; received institutional support for research from BMS. CR reports speaker from MSD and GuardantHealth, scientific advisor Mylan, institutional research collaboration Biomark Inc., non-remunerated collaboration with OncoDNA, and steering scientific committee for Oncopass. DT received honoraria from Merck, Pfizer, Novartis, Boehringer Ingelheim, Roche, Takeda; performed as a advisory-consultancy for Novartis, Bayer, Boehringer Ingelheim, Celgene, Astra Zeneca, Eli-lily, Loxo; received research grant from Novartis, Astra Zeneca, GlaxoSmithKline, Bayer, Pfizer; received travel/accommodation expenses from Merck, Pfizer, Novartis, Boehringer Ingelheim, Roche, Takeda. JV is a consultancy or advisory functions for AstraZeneca, BMS, Boehringer Ingelheim, MSD, Pfizer, Roche; is a lectures for AstraZeneca, Boehringer Ingelheim, MSD, Roche, BMS. HW received honoraria from Ariad, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Genentech/Roche, LOXO, Merck, PharmaMar, Pfizer, Spectrum, Takeda; speakers bureau for AZ, Genentech/Roche, Merck. BB reports grants from Abbvie, grants from Amgen, grants from AstraZeneca, grants from Biogen, grants from Blueprint Medicines, grants from BMS, grants from Celg{\`e}ne, grants from Eli-Lilly, grants from GSK, grants from Ignyta, grants from IPSEN, grants from Merck KGaA, grants from MSD, grants from Nektar, grants from Onxeo, grants from Pfizer, grants from Pharma Mar, grants from Sanofi, grants from Spectrum Pharmaceuticals, grants from Takeda, grants from Tiziana Pharma, outside the submitted work.",

year = "2019",

month = nov,

doi = "10.1093/annonc/mdz295",

language = "English",

volume = "30",

pages = "1686--1688",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "11",

}

Mountzios, G, Remon, J, Novello, S, Blais, N, Califano, R, Cufer, T, Dingemans, AM, Liu, SV, Peled, N, Pennell, NA, Reck, M, Rolfo, C, Tan, D, Vansteenkiste, J, West, H & Besse, B 2019, 'Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration', Annals of Oncology, vol. 30, no. 11, pp. 1686-1688. https://doi.org/10.1093/annonc/mdz295

Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration. / Mountzios, G.; Remon, J.; Novello, S. et al.
In: Annals of Oncology, Vol. 30, No. 11, 11.2019, p. 1686-1688.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration

AU - Mountzios, G.

AU - Remon, J.

AU - Novello, S.

AU - Blais, N.

AU - Califano, R.

AU - Cufer, T.

AU - Dingemans, A. M.

AU - Liu, S. V.

AU - Peled, N.

AU - Pennell, N. A.

AU - Reck, M.

AU - Rolfo, C.

AU - Tan, D.

AU - Vansteenkiste, J.

AU - West, H.

AU - Besse, B.

N1 - Funding Information: GM received honoraria/consultancy from AstraZeneca, Roche, Pfizer, BMS, MSD, Takeda, Boehringer, Merck, Novartis, Amgen; received travel fees from AstraZeneca, Roche, Pfizer, BMS, MSD, Takeda, Boehringer, Merck, Novartis, Astellas, Pierre Fabre. JR: Other from MSD (advisory), other from BOEHRINGER (advisory), other from PFIZER (advisory), personal fees and other from OSE IMMUNOTHERAPEUTICS (travel), other from BMS (travel and advisory), other from ASTRAZENECA (travel and advisory), other from ROCHE (travel), outside the submitted work. SN is a advisor/speaker bureau for Astra Zeneca, BI, Celgene, Eli Lilly, MSD, Takeda, Pfizer, Roche, BMS, Abbvie. NB is a consultant honorarium to Pfizer, AZ, BMS, Merck, BI, Novartis, Takeda, Sanofi, Roche; received research grants from CCTG, Astra Zeneca. RC received honoraria and consultancy fees from AstraZeneca, Boehringer Ingelheim, Lilly Oncology, Roche, Pfizer, MSD, BMS, Takeda, and Novartis. TC received honoraria for lectures and advisory board consultations from AstraZeneca. AMD is an advisory board member of BMS, MSD, Roche, Eli Lilly, Takeda, Pfizer, Boehringer Ingelheim (all institution); received research grant from BMS (institution); received research support from Abbvie (institution). SL is an advisory board/consultant of Apollomics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Guardant Health, Heron, Ignyta, Inivata, Janssen, Lilly, Merck, Pfizer, Regeneron, Taiho (DSMB), Takeda/Ariad, Tempus; received research grant (institution) from Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Clovis, Corvus, Debiopharm, Esanex, Genentech/Roche, Ignyta, Lilly, Lycera, Merck, Molecular Partners, OncoMed, Pfizer, Rain Therapeutics. NP is an advisor for and honorarium from AstraZeneca, AID Genomics, Boehringer-Ingelheim, BMS, E.Lilly, MSD, Novartis, Pfizer, Roche, NovellusDx, FMI, Gaurdant360. NP received consulting fees from AstraZeneca, Merck, Eli Lilly, BMS, and Cota. MR: Amgen, Abbvie, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, Roche; received institutional support for research from BMS. CR reports speaker from MSD and GuardantHealth, scientific advisor Mylan, institutional research collaboration Biomark Inc., non-remunerated collaboration with OncoDNA, and steering scientific committee for Oncopass. DT received honoraria from Merck, Pfizer, Novartis, Boehringer Ingelheim, Roche, Takeda; performed as a advisory-consultancy for Novartis, Bayer, Boehringer Ingelheim, Celgene, Astra Zeneca, Eli-lily, Loxo; received research grant from Novartis, Astra Zeneca, GlaxoSmithKline, Bayer, Pfizer; received travel/accommodation expenses from Merck, Pfizer, Novartis, Boehringer Ingelheim, Roche, Takeda. JV is a consultancy or advisory functions for AstraZeneca, BMS, Boehringer Ingelheim, MSD, Pfizer, Roche; is a lectures for AstraZeneca, Boehringer Ingelheim, MSD, Roche, BMS. HW received honoraria from Ariad, AstraZeneca, Boehringer-Ingelheim, BMS, Celgene, Genentech/Roche, LOXO, Merck, PharmaMar, Pfizer, Spectrum, Takeda; speakers bureau for AZ, Genentech/Roche, Merck. BB reports grants from Abbvie, grants from Amgen, grants from AstraZeneca, grants from Biogen, grants from Blueprint Medicines, grants from BMS, grants from Celgène, grants from Eli-Lilly, grants from GSK, grants from Ignyta, grants from IPSEN, grants from Merck KGaA, grants from MSD, grants from Nektar, grants from Onxeo, grants from Pfizer, grants from Pharma Mar, grants from Sanofi, grants from Spectrum Pharmaceuticals, grants from Takeda, grants from Tiziana Pharma, outside the submitted work.

PY - 2019/11

Y1 - 2019/11

KW - NIVOLUMAB

KW - DOCETAXEL

KW - 1ST-LINE

U2 - 10.1093/annonc/mdz295

DO - 10.1093/annonc/mdz295

M3 - Editorial

C2 - 31504132

SN - 0923-7534

VL - 30

SP - 1686

EP - 1688

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Mountzios G, Remon J, Novello S, Blais N, Califano R, Cufer T et al. Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of >= 1% by the USA Food and Drug Administration. Annals of Oncology. 2019 Nov;30(11):1686-1688. doi: 10.1093/annonc/mdz295